PL1845945T3 - Wytwarzanie postaci dawkowania ze stałą dyspersją mikrokrystalicznego związku aktywnego - Google Patents
Wytwarzanie postaci dawkowania ze stałą dyspersją mikrokrystalicznego związku aktywnegoInfo
- Publication number
- PL1845945T3 PL1845945T3 PL06706797T PL06706797T PL1845945T3 PL 1845945 T3 PL1845945 T3 PL 1845945T3 PL 06706797 T PL06706797 T PL 06706797T PL 06706797 T PL06706797 T PL 06706797T PL 1845945 T3 PL1845945 T3 PL 1845945T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- active agent
- dosage forms
- solid dispersion
- microcrystalline active
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000007962 solid dispersion Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05002955A EP1690528A1 (de) | 2005-02-11 | 2005-02-11 | Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs |
| PCT/EP2006/001164 WO2006084696A1 (de) | 2005-02-11 | 2006-02-09 | Herstellung von dosierungsformen mit einer festen dispersion eines mikrokristallinen wirkstoffs |
| EP06706797.5A EP1845945B1 (de) | 2005-02-11 | 2006-02-09 | Herstellung von dosierungsformen mit einer festen dispersion eines mikrokristallinen wirkstoffs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1845945T3 true PL1845945T3 (pl) | 2018-05-30 |
Family
ID=34933712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06706797T PL1845945T3 (pl) | 2005-02-11 | 2006-02-09 | Wytwarzanie postaci dawkowania ze stałą dyspersją mikrokrystalicznego związku aktywnego |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10653625B2 (pl) |
| EP (2) | EP1690528A1 (pl) |
| JP (1) | JP5441339B2 (pl) |
| CA (1) | CA2597549C (pl) |
| DK (1) | DK1845945T3 (pl) |
| PL (1) | PL1845945T3 (pl) |
| WO (1) | WO2006084696A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008138755A2 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| WO2009114420A2 (en) * | 2008-03-07 | 2009-09-17 | Eveready Battery Company, Inc. | Shaving aid material |
| EP2140861A1 (en) * | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
| CA2745456A1 (en) * | 2008-12-05 | 2010-06-10 | Bayer Animal Health Gmbh | Extrudate having spicular active substances |
| EP2359812A1 (en) * | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
| EP2675434A1 (en) * | 2011-02-17 | 2013-12-25 | F.Hoffmann-La Roche Ag | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
| WO2013132457A2 (en) * | 2012-03-07 | 2013-09-12 | National Institute Of Pharmaceutical Education And Research (Niper) | Nanocrystalline solid dispersion compositions and process of preparation thereof |
| US10339795B2 (en) | 2013-12-24 | 2019-07-02 | Lutron Technology Company Llc | Wireless communication diagnostics |
| JP6867035B2 (ja) * | 2015-12-10 | 2021-04-28 | 国立大学法人千葉大学 | 結晶質薬物ナノ粒子の製造方法 |
| US10285987B2 (en) | 2017-04-28 | 2019-05-14 | Amplipharm Pharmaceuticals, LLC | Device and kit for dosing and dispensing non-liquid medicine |
| US9949967B2 (en) | 2016-04-28 | 2018-04-24 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
| CA3062764A1 (en) * | 2016-04-28 | 2017-11-02 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
| US10792249B2 (en) | 2017-07-24 | 2020-10-06 | Acryspharm Llc | High drug loading pharmaceutical compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2156215B (en) | 1984-03-05 | 1988-03-02 | Nitto Electric Ind Co | Percutaneous absorption type adhesive pharmaceutical preparation |
| JPS6110507A (ja) * | 1984-06-14 | 1986-01-18 | サンド・アクチエンゲゼルシヤフト | 新規遅効性製剤 |
| NL194389C (nl) | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
| CH670201A5 (en) * | 1985-06-03 | 1989-05-31 | Sandoz Ag | Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix |
| AU643210B2 (en) * | 1989-05-16 | 1993-11-11 | Medice Chem.-Pharm. Fabrik Putter Gmbh & Co. Kg | Process for preparing optically active 2-aryl-alkanoic acids, in particular 2-ayrl-propionic acids |
| AU1537292A (en) * | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| MX9301817A (es) | 1992-03-30 | 1994-01-31 | Alza Corp | Sistema polimerico que contiene un compuesto parcialmente soluble. |
| NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
| CA2214895C (en) * | 1997-09-19 | 1999-04-20 | Bernard Charles Sherman | Improved pharmaceutical composition comprising fenofibrate |
| WO1999021534A1 (en) * | 1997-10-27 | 1999-05-06 | Merck Patent Gmbh | Solid state solutions and dispersions of poorly water soluble drugs |
| AU3666799A (en) * | 1998-04-27 | 1999-11-16 | Dow Chemical Company, The | Encapsulated active materials |
| US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
| JP2004267041A (ja) * | 2003-03-06 | 2004-09-30 | Sanei Gen Ffi Inc | 微細化固形物分散製剤およびその製造方法 |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
-
2005
- 2005-02-11 EP EP05002955A patent/EP1690528A1/de not_active Withdrawn
-
2006
- 2006-02-09 DK DK06706797.5T patent/DK1845945T3/en active
- 2006-02-09 JP JP2007554502A patent/JP5441339B2/ja not_active Expired - Lifetime
- 2006-02-09 EP EP06706797.5A patent/EP1845945B1/de not_active Expired - Lifetime
- 2006-02-09 WO PCT/EP2006/001164 patent/WO2006084696A1/de not_active Ceased
- 2006-02-09 US US11/884,164 patent/US10653625B2/en active Active
- 2006-02-09 PL PL06706797T patent/PL1845945T3/pl unknown
- 2006-02-09 CA CA2597549A patent/CA2597549C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006084696A9 (de) | 2007-10-25 |
| CA2597549A1 (en) | 2006-08-17 |
| DK1845945T3 (en) | 2018-02-26 |
| JP2008543724A (ja) | 2008-12-04 |
| WO2006084696A1 (de) | 2006-08-17 |
| EP1845945B1 (de) | 2017-11-22 |
| US10653625B2 (en) | 2020-05-19 |
| CA2597549C (en) | 2015-01-20 |
| EP1845945A1 (de) | 2007-10-24 |
| JP5441339B2 (ja) | 2014-03-12 |
| EP1690528A1 (de) | 2006-08-16 |
| US20090012184A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1743882T3 (pl) | Sposób do produkcji izocyjanianów | |
| IL188330A0 (en) | Processes for the preparation of | |
| IL185390A (en) | A solid dosage form | |
| IL194522A0 (en) | Process for the preparation of prasugrel | |
| IL196234A0 (en) | A process for the preparation of optically active cyclopropylamines | |
| IL184562A (en) | Polymorph ivandront a, a process for its preparation and pharmaceutical preparations containing it | |
| ZA200706421B (en) | Novel processes for the preparation of a 2H-chromene | |
| ZA200709788B (en) | Cannabinold active pharmaceutical ingredient for Improved dosage forms | |
| PL1856038T3 (pl) | Sposób wytwarzania zawierającego mocznik strumienia wodnego | |
| IL191758A0 (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
| ZA200804264B (en) | Process for the preparation of ferri-succinylcasein | |
| EP1976490A4 (en) | EXTENDED RELEASE TABLET CONTAINING ZALTOPROFEN AND PROCESS FOR PREPARING SAID TABLET | |
| PT1748990E (pt) | Processo para a preparação de telmisartan | |
| GB0402492D0 (en) | Pharmaceutically active compounds | |
| EP1937223A4 (en) | PELLET FORMULATION OF AN ALPHA1 RECEPTOR ANTAGONIST WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF | |
| IL213474A0 (en) | Processes for the preparation of cyclopropyl-amide derivatives | |
| IL186220A0 (en) | Processes for the preparation of atomoxetine hydrochloride | |
| IL184193A0 (en) | Processes for the preparation of aminoethoxybenzyl alcohols | |
| IL195062A0 (en) | Process for the preparation of solid sterile active pharmaceutical ingredient | |
| ZA200601910B (en) | Process for the preparation of organosilances | |
| PL1795186T5 (pl) | Preparat leku zawierający flupirtynę o kontrolowanym uwalnianiu substancji czynnej | |
| ZA200703495B (en) | Process for the preparation of irbesartan hydrochloride | |
| ZA200901118B (en) | Formulations for the controlled release of agrochemical active agents | |
| PL1700855T3 (pl) | Sposób wytwarzania tazarotenu | |
| ZA200707910B (en) | Contraceptive pharmaceutical preparation |